Global Angioimmunoblastic T-Cell Lymphoma Market - 2024-2031

Overview

Global angioimmunoblastic T-cell lymphoma Market reached US$ 478.5 million in 2023 and is expected to reach US$ 687 million by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031.

Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of non-Hodgkin lymphoma (NHL) that develops when lymphocytes grow out of control. These lymphocytes move around the body in the blood and lymphatic system, which is an essential part of the immune system. The lymphatic system consists of lymph vessels that carry a liquid called lymph, which circulates around body tissues and contains a high number of white blood cells.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of non-Hodgkin lymphoma

The increasing number of NHL cases leads to a greater focus on developing targeted therapies and personalized treatment options for various NHL subtypes, including AITL. Pharmaceutical companies and research institutions are motivated to invest in research and development to address the needs of this patient population, resulting in the introduction of new drugs and therapies. For instance, according to the National Institutes of Health, the rate of new cases of non-Hodgkin lymphoma was 18.6 per 100,000 men and women per year. The death rate was 5.0 per 100,000 men and women per year.

Limited availability of specialized therapies

One significant restraint in the global AITL market is the high cost of treatment and limited availability of specialized therapies. Many of the advanced treatments, including targeted therapies and CAR-T cell therapies, come with substantial financial burdens that can restrict access for patients, especially in low- and middle-income countries.

The complexity and high cost of manufacturing these therapies, coupled with the limited number of approved drugs for AITL, pose challenges in making these treatments widely accessible, thereby inhibiting market growth.

Segment Analysis

The global angioimmunoblastic T-cell lymphoma market is segmented based on drug type, route of administration, distribution channel, and region.

The azacitidine from the drug type segment accounted for approximately 41.7% of the angioimmunoblastic t-cell lymphoma market share

The azacitidine from the drug type segment accounted for approximately 41.7%. Azacitidine is a crucial treatment for angioimmunoblastic T-cell lymphoma (AITL) due to its role in epigenetic regulation. It inhibits DNA methylation, reactivating tumor suppressor genes and enhancing the effectiveness of other therapies. It is often used in combination treatment, especially in cases where traditional chemotherapy is insufficient or patients experience relapse or refractory disease. Azacitidine targets underlying epigenetic abnormalities associated with AITL, improving clinical outcomes. However, its effectiveness varies among patients and may cause side effects like bone marrow suppression, anemia, and gastrointestinal disturbances. Therefore, its use is tailored to individual patient needs.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, ongoing clinical trials and research studies, expansions, increased healthcare infrastructure, and others that help the region to grow during the forecast period.

For instance, in March 2023, Duvelisib treatment significantly improved response rates in patients with peripheral T-cell lymphoma (PTCL), with activity favoring those with PTCL not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma (AITL), according to histology-specific outcomes from the phase 2 PRIMO trial.

Market Segmentation

By Drug Type

• Azacitidine
• Brentuximab Vedotin
• Tipifarnib
• AUT04
• MLN8237
• CD7-CART
• Others

By Route of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Roche (Genentech), Bristol-Myers Squibb, Merck & Co, Pfizer Inc, Novartis, Celgene Corporation (Bristol-Myers Squibb Company), Gilead Sciences, AbbVie, Incyte Corporation, Janssen Pharmaceuticals (Johnson & Johnson) among others.

Key Developments

• In May 2023, A phase 2 clinical trial by the University School of Medicine found that 90% of patients with an aggressive subtype of non-Hodgkin lymphoma have gone into remission. The trial, which included 17 patients with peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH), found that 80.2 percent of them had complete responses after a treatment course that combined a standard four-drug chemotherapy regimen with another drug called azaciditine.

Why Purchase the Report?

• To visualize the global angioimmunoblastic T-cell lymphoma market segmentation based on drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the angioimmunoblastic T-cell lymphoma market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global angioimmunoblastic T-cell lymphoma market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies